EVM
VERV

Eaton Vance Management’s Verve Therapeutics VERV Stock Holding History

Eaton Vance Management’s Portfolio VERV Stock Details VERV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-330
Closed -$12K – 2688
2021
Q4 		$12K Hold
330
– – ﹤0.01% 2510
2021
Q3 		$16K Buy
+330
New +$19.4K ﹤0.01% 1677

Other funds holding VERV

AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

Eaton Vance Management's VERV Position: Q1 2022 in Review

Eaton Vance Management sold out of Verve Therapeutics (VERV) in Q1 2022, closing a stake of 330 shares — an estimated $12K sold.

Eaton Vance Management first reported a position in VERV in Q3 2021 and held it in 2 quarters. The position peaked at $16K in Q3 2021. 92 funds tracked by Wall St. Rank hold VERV as of Q1 2022.

  • Eaton Vance Management reported no remaining Verve Therapeutics position as of Q1 2022 after selling out during the quarter.
  • Eaton Vance Management sold 330 Verve Therapeutics shares in Q1 2022, an estimated $12K.
  • Eaton Vance Management first reported a position in Verve Therapeutics in Q3 2021 and held it in 2 quarters.
  • Eaton Vance Management's Verve Therapeutics position peaked at $16K in Q3 2021.
  • 92 funds tracked by Wall St. Rank held Verve Therapeutics as of Q1 2022.

Based on Eaton Vance Management's 13F filing for Q1 2022, filed 16 May 2022.